Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
105 hedge funds and large institutions have $820M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 37 increasing their positions, 8 reducing their positions, and 4 closing their positions.
1,325% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 4
721% more capital invested
Capital invested by funds: $99.9M → $820M (+$720M)
363% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 8
102% more funds holding
Funds holding: 52 → 105 (+53)
62% less call options, than puts
Call options by funds: $661K | Put options by funds: $1.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$71.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$62.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$46.6M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$30.1M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$21.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$21.4M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.82M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.51M |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$1.4M |
| 5 |
JP Morgan Chase
New York
|
-$644K |
LBPH Hedge Fund Activity: Q1 2024 in Review
105 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q1 2024, worth a combined $820M — up 721% from $99.9M a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new LBPH positions and 4 closed out — a net gain of 53 holders — while 37 added to existing stakes and 8 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $71.7M. The largest seller was Ikarian Capital, cutting an estimated $21.4M.
- 105 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q1 2024, up from 52 in Q4 2023.
- Funds reported $820M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q1 2024, up 721% quarter-over-quarter.
- 57 funds opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 4 closed out, a net change of +53 holders.
- The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was RA Capital Management, an estimated $71.7M added.
- The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was Ikarian Capital, an estimated $21.4M sold.
Based on aggregated 13F filings for Q1 2024.